Computational Analysis of Pyridopyrimidine-based Polo Like Kinase 2 (PLK2) Inhibitors: Examining the Structural Basis for Anticancer Activity

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|14|5|581-596

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.14, Iss.5, 2017-04, pp. : 581-596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-12 ,pp. : 2014-2025

Bentham Science Publishers

Access to resources Recommend Favorite

Structural Basis for Interaction of Inhibitors with Cyclin-Dependent Kinase 2

By  

Current Computer - Aided Drug Design, Vol. 1, Iss. 1, 2005-01 ,pp. : 53-64

Bentham Science Publishers

Access to resources Recommend Favorite

Progress in the Discovery of Polo-like Kinase Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 2, 2005-04 ,pp. : 181-197

Bentham Science Publishers

Access to resources Recommend Favorite

2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase

By  

Current Computer - Aided Drug Design, Vol. 12, Iss. 3, 2016-09 ,pp. : 229-240

Bentham Science Publishers

Access to resources Recommend Favorite

A Case Study from the Chemistry Core of the Pittsburgh Molecular Library Screening Center: The Polo-like Kinase Polo-Box Domain (Plk1- PBD)

By  

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 13, 2009-09 ,pp. : 1194-1205

Bentham Science Publishers

Access to resources Recommend Favorite